Similar articles

• The chances of a patient with melanoma developing in transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB).

  Russell-Jones R, Powell AM, Acland K, Calonje E, O'Doherty M, Healy C. Russell-Jones R, et al. Eur J Surg Oncol. 2005 Mar;31(2):210-1. doi: 10.1016/j.ejso.2004.10.009. Eur J Surg Oncol. 2005. PMID: 15698741 No abstract available.
• Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark.

  Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JE. Pawlik TM, et al. Eur J Surg Oncol. 2005 Apr;31(3):323-4. doi: 10.1016/j.ejso.2004.11.010. Eur J Surg Oncol. 2005. PMID: 15780572 No abstract available.
• Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.

  Thomas JM, Clark MA. Thomas JM, et al. Eur J Surg Oncol. 2004 Aug;30(6):686-91. doi: 10.1016/j.ejso.2004.04.004. Eur J Surg Oncol. 2004. PMID: 15256245 Review.
• [Sentinel lymph node biopsy and incidence of recurrence].

  [No authors listed] [No authors listed] Hautarzt. 2006 Mar;57(3):182. Hautarzt. 2006. PMID: 17429861 German. No abstract available.
• Sentinel node mapping for melanoma: results of trials and current applications.

  Thompson JF, Shaw HM. Thompson JF, et al. Surg Oncol Clin N Am. 2007 Jan;16(1):35-54. doi: 10.1016/j.soc.2006.10.013. Surg Oncol Clin N Am. 2007. PMID: 17336235 Review.